I think we all would like some intelligent discussion but that seems to be a distant dream now these threads have been hijacked by holders apparently in despair over their holdings.
The recent quarterly suggests R&D expected this quarter and a net positive outcome expected which i assume means income should be more than outgoings this next 4c.
I don't think it really matters too much when the R&D refund is received, with the expansion of trial programmes detailed in recent reports it seems fairly apparent more finance will be requited at some point soon. This in itself is not necessarily a problem. They have stated for some time they have been in discussions with various pharma companies. Who knows maybe they will be able to sign a surprising deal with one of tgese vompanies out of left field. Certainly if the product works it is currently at a huge discount and someone might want a big chunk? Certainly cant buy a large holding on market without pushing up price
Even a placement with premium to current sp would be good. I know mr willy will just rain doom on this but to daye in my opinion the management have done well to get this far with still low shares on issue. Even now they could still raise another 30 mil and still only add 60 million shares. Look at similar companies with 700 million to billions of shares on issue.
imo the only thing killing sp at the moment is the absolute and obviously deliberate silence on burns trial progress. Something must be happening there in the background.
- Forums
- ASX - By Stock
- RCE
- Ann: Quarterly Activities/Appendix 4C Cash Flow Report
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-33
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RCE (ASX) to my watchlist
(20min delay)
|
|||||
Last
48.0¢ |
Change
0.010(2.13%) |
Mkt cap ! $111.2M |
Open | High | Low | Value | Volume |
47.0¢ | 48.0¢ | 46.5¢ | $71.45K | 151.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 9621 | 47.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
48.0¢ | 5 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 9621 | 0.470 |
1 | 9622 | 0.465 |
4 | 33259 | 0.460 |
2 | 19916 | 0.455 |
3 | 66668 | 0.450 |
Price($) | Vol. | No. |
---|---|---|
0.480 | 5 | 1 |
0.500 | 51020 | 1 |
0.505 | 5942 | 1 |
0.510 | 11000 | 1 |
0.540 | 6758 | 1 |
Last trade - 16.10pm 13/11/2024 (20 minute delay) ? |
Featured News
RCE (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online